Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168930 · ClinicalTrials.gov registry record · Phase 2
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT05168930: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Dana-Farber Cancer Institute.
NCT05168930 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 190-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05168930, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Primary Outcome
Assessed by flow cytometry (FC)
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Venetoclax
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- South Shore Hospital - South Weymouth
Maine
- New England Cancer Specialists - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2028-10-28 |
| Phase | Phase 2 |
What NCT05168930 shows while recruiting
NCT05168930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 190-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT05168930 reports a single indexed study location in Massachusetts, Maine.
Frequently Asked Questions
What is clinical trial NCT05168930 about?
NCT05168930 is a clinical study titled "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)". This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
What is the current status of trial NCT05168930?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2022-02-18. Estimated completion is 2028-10-28.
What conditions does trial NCT05168930 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT05168930?
The interventions under investigation include: Zanubrutinib (DRUG), Venetoclax (DRUG).
Who is sponsoring clinical trial NCT05168930?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05168930 being conducted?
This trial has 4 study locations across Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05168930's enrollment target sits among peer trials
45 19th of 29 higher than 11 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI